SaNOtize has raised a $24 million series B round, giving it the cash to fund its ongoing phase 3 COVID-19 prevention trial and other research into its nitric oxide nasal spray (NONS).

SaNOtize bags $24M to fund phase 3 trial of COVID-19 nasal spray